WO1996027003A1 - A process for the preparation of factor ix from biological sources - Google Patents

A process for the preparation of factor ix from biological sources Download PDF

Info

Publication number
WO1996027003A1
WO1996027003A1 PCT/EP1996/000636 EP9600636W WO9627003A1 WO 1996027003 A1 WO1996027003 A1 WO 1996027003A1 EP 9600636 W EP9600636 W EP 9600636W WO 9627003 A1 WO9627003 A1 WO 9627003A1
Authority
WO
WIPO (PCT)
Prior art keywords
factor
process according
protein precipitant
virus inactivation
chromatography
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1996/000636
Other languages
French (fr)
Inventor
Djuro Josic
Lutz Hoffer
Frank Morfeld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Octapharma AG
Original Assignee
Octapharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002213577A priority Critical patent/CA2213577C/en
Priority to JP8525986A priority patent/JPH11500910A/en
Priority to AT96904778T priority patent/ATE194167T1/en
Priority to EP96904778A priority patent/EP0811058B1/en
Priority to AU48761/96A priority patent/AU697217B2/en
Priority to DE69609054T priority patent/DE69609054T2/en
Priority to UA97084352A priority patent/UA46005C2/en
Priority to US08/894,654 priority patent/US5919909A/en
Application filed by Octapharma AG filed Critical Octapharma AG
Priority to EA199700196A priority patent/EA000222B1/en
Priority to DK96904778T priority patent/DK0811058T3/en
Publication of WO1996027003A1 publication Critical patent/WO1996027003A1/en
Priority to FI973469A priority patent/FI119377B/en
Anticipated expiration legal-status Critical
Priority to GR20000401725T priority patent/GR3034035T3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Definitions

  • the present invention pertains to a process for the preparation of factor IX from biological sources by chromatography as well as to factor IX obtainable by the process according to the inven ⁇ tion.
  • the cryoprecipitate is first separated.
  • the frozen citrate plasma is thawed and the major amount of factor VIII and fibrinogen is separated by centrifugation.
  • the cryopoor plasma thus obtained contains the vitamin K dependent coagulation factors with an activity in the order of magnitude of 0.01 IU/ g of protein.
  • the vitamin K dependent coagulation factors are bound by extraction with anion exchangers, such as DEAE Sephadex, without adversely af ⁇ fecting albumin recovery.
  • anion exchangers such as DEAE Sephadex
  • this step must usually be performed as a solid phase extraction in batch operation.
  • the fractions obtained after elution of the DEAE Sephadex then serve as the starting material for the purification of factor IX.
  • Proteases contained in the plasma are also enriched in this fraction, resulting in yield losses of the material of interest, factor IX, by proteolytic digestion and an increase of the risk of thrombogenity of the preparation.
  • the object of the invention is to provide a process which reduces the risks mentioned without the addition of protease inhibitors. Surprisingly, this object is achieved by a process with the fea ⁇ tures of the claim. This involves treating the biological source containing factor IX with a protein precipitant.
  • Candidate bio ⁇ logical sources are, in particular, blood plasma or cryoprecip- itate depleted of factor VIII and fibrinogen (cryopoor plasma) .
  • the concentration of the protein precipitant is, in particular, from 1.5 to 2.3 mol/1, preferably from 1.75 to 1.9 mol/1.
  • the values relate to the protein precipitant concentrations present in the sources containing factor IX (final concentration) .
  • ammonium sulfate is considered in particular.
  • the process according to the invention reduces the proteolytic activity by at least one order of magnitude.
  • interfering components such as factor VII and factor II
  • factor VII and factor II are removed by the precipitation step prior to the actual chromato- graphic purification of factor IX.
  • Proteins C and S are also depleted. In the case of factor VII, almost complete elimination can be achieved.
  • Factor II is also depleted rather completely (70 to 90%) whereas depletion of proteins C and S is about 50%.
  • the activity of factor IX is typically from 20 to 30 IU/ml, corresponding to a specific activity of 1 to 5 IU/mg.
  • the precipitation step according to the invention is followed by the chromatographic sepa ⁇ ration of the fraction enriched in factor IX.
  • factor IX is preferably bound in the presence of relatively high salt concentrations, which are present from protein precipitation, to a chromatographic material capable of being employed for hydrophobic interaction chromatography (HIC) .
  • HIC hydrophobic interaction chromatography
  • a chromato ⁇ graphic material may be used which has bound on the substrate material a hydrophilic flexible arm (tentacle) . Covalently bound to these spacers are then the corresponding ligands, in particu ⁇ lar hydrophobic ligands, such as propyl, butyl, phenyl groups.
  • the supernatant of the fraction treated with the protein precipi ⁇ tant is applied to the appropriate chromatographic material and optionally washed. Elution of the factor IX bound to the column and still containing factor X can be performed with a buffer containing the protein precipitant in a lower concentration, the ionic strength of the eluent solution thus being reduced with respect to that of the application solution.
  • the fraction com ⁇ prising factor IX eluting from the chromatographic column which contains HIC material is collected and subjected to further desalting steps using appropriate means. This can be performed, for instance, by ultrafiltration and/or diafiltration.
  • factor IX for example, from accompanying factor X
  • affinity chromatography on a heparin modified substrate.
  • the ionic strength of the solution containing the factors is relatively low, the latter will bind to the chromato ⁇ graphic material.
  • Elution of interfering factor X, if any, is achieved by treatment with a solution containing sodium chloride in concentrations of from 150 to 300 mmol/1. Under such condi ⁇ tions, factor IX will remain bound to the heparin affinity substrate.
  • factor IX starts separating from the surface of the affinity substrate.
  • Virus inactivation may be performed by chemical and/or physical processes.
  • the physical virus inactivation method essentially consists in heat, treating the respective fraction at 60 to 65°C for 5 to 30 hours. Such heat treatment can be performed, in particular, following the heparin affinity chromatography.
  • the chemical virus inactivation consists, for example, in a treatment of a fraction containing factor IX with non-ionic surfactants and dialkyl or trialkyl phosphates. In particular, combinations of Tween and tri-n-butyl phosphate (TNBP) may be used.
  • Methods of virus inactivation are described in EP 0131740 or in Horowitz et al., Blood, 79 (1992) 826.
  • Virus inactivation methods may also be combined, such as described in WO 94/17834.
  • chemical virus inactivation is performed after the ultrafiltration/diafiltration following the hydrophobic chromatography.
  • the overall yield of high purity factor IX can be increased to 20 to 30%, based on plasma.
  • the figure shows the process according to the invention with subsequent chromatographic purification steps in the form of a flow chart.
  • the arrows indicate which fractions are separated off and which remain in the corresponding eluates and supernatants.
  • Frozen citrate plasma is thawed and agitated at 0 to 3°C.
  • Factor VIII and fibrinogen are separated by centrifugation.
  • the cryopoor plasma fraction obtained contains vitamin K dependent coagulation factors with a specific activity of about 0.01 IU/mg of protein.
  • the subsequent capture step includes solid phase extraction or chromatography on DEAE ion exchangers, separating IgG and albumin.
  • the vitamin K dependent coagulation factors are present in an activity of from 10 to 50 IU/ml, corresponding to an enrichment factor of about 3500, based on factor IX.
  • the capture step is now followed by the actual purification.
  • an ammonium sulfate solution to give a final concentration of about 1.9 mol/1.
  • C and S proteins are removed by about 50% whereas factor II is removed by 70 to 90% and factor VII almost quantita- tively.
  • the supernatant obtained from the ammonium sulfate precipitation is subjected to hydrophobic interaction chromato ⁇ graphy on an appropriately modified tentacle gel.
  • the concentra ⁇ tion of ammonium sulfate in the application solution was about 1.75 mol/1.
  • the application buffer also contains phosphate ions. Hydrophobic interaction chromatography will result in residual factor VII and factor IX being bound.
  • Factor X will bind to the material at 70 to 80%. Elution of the factor IX/factor X mixture is performed with a solution of ammonium sulfate containing from 1.2 to 1.4 mol/1. The eluent is free of factor VII and has essentially no proteolytic activity. The specific activity of factor IX in the factor IX/factor X mixture is from 5 to 15 IU/mg of protein.
  • the ammonium sulfate present in the eluate is removed by ultra- filtration and diafiltration.
  • Virus inactivation with detergents is performed by treatment with about 1% Tween 80/0.3% TNBP.
  • Factors X and IX will bind to the heparin gel at low osmolarities .
  • Factor X is obtained by washing with a buffer containing 0.25 mol/1 of NaCl .
  • Factor IX will elute upon increasing the sodium chloride con ⁇ centration to 0.45 mol/1. Thereafter, factor IX is present in the eluate at 30 to 50 IU/ml with a specific activity of > 100.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

A process for the preparation of factor IX from biological sources by chromatography, characterized in that prior to any chromatographic separations said source is treated with a protein precipitant.

Description

A Process for the Preparation of Factor IX from Biological Sources
The present invention pertains to a process for the preparation of factor IX from biological sources by chromatography as well as to factor IX obtainable by the process according to the inven¬ tion.
When factor IX is prepared, for example, from blood plasma, the cryoprecipitate is first separated. The frozen citrate plasma is thawed and the major amount of factor VIII and fibrinogen is separated by centrifugation. The cryopoor plasma thus obtained contains the vitamin K dependent coagulation factors with an activity in the order of magnitude of 0.01 IU/ g of protein.
According to the process known from the prior art, the vitamin K dependent coagulation factors are bound by extraction with anion exchangers, such as DEAE Sephadex, without adversely af¬ fecting albumin recovery. However, due to the poor flow charac¬ teristics of DEAE Sephadex, this step must usually be performed as a solid phase extraction in batch operation. The fractions obtained after elution of the DEAE Sephadex then serve as the starting material for the purification of factor IX. Proteases contained in the plasma, however, are also enriched in this fraction, resulting in yield losses of the material of interest, factor IX, by proteolytic digestion and an increase of the risk of thrombogenity of the preparation.
The object of the invention is to provide a process which reduces the risks mentioned without the addition of protease inhibitors. Surprisingly, this object is achieved by a process with the fea¬ tures of the claim. This involves treating the biological source containing factor IX with a protein precipitant. Candidate bio¬ logical sources are, in particular, blood plasma or cryoprecip- itate depleted of factor VIII and fibrinogen (cryopoor plasma) .
The concentration of the protein precipitant is, in particular, from 1.5 to 2.3 mol/1, preferably from 1.75 to 1.9 mol/1. The values relate to the protein precipitant concentrations present in the sources containing factor IX (final concentration) .
As the protein precipitant, ammonium sulfate is considered in particular.
The process according to the invention reduces the proteolytic activity by at least one order of magnitude. In addition, interfering components, such as factor VII and factor II, are removed by the precipitation step prior to the actual chromato- graphic purification of factor IX. Proteins C and S are also depleted. In the case of factor VII, almost complete elimination can be achieved. Factor II is also depleted rather completely (70 to 90%) whereas depletion of proteins C and S is about 50%.
In the supernatant of the fraction treated with the protein precipitant, the activity of factor IX is typically from 20 to 30 IU/ml, corresponding to a specific activity of 1 to 5 IU/mg.
The precipitation step according to the invention, preferably using ammonium sulfate, is followed by the chromatographic sepa¬ ration of the fraction enriched in factor IX. This takes advan¬ tage of the fact that at high salt concentrations proteins can undergo hydrophobic interactions to different extents. According to the invention, factor IX is preferably bound in the presence of relatively high salt concentrations, which are present from protein precipitation, to a chromatographic material capable of being employed for hydrophobic interaction chromatography (HIC) . This at the same time reduces the high salt concentration resulting from protein precipitation. In particular, a chromato¬ graphic material may be used which has bound on the substrate material a hydrophilic flexible arm (tentacle) . Covalently bound to these spacers are then the corresponding ligands, in particu¬ lar hydrophobic ligands, such as propyl, butyl, phenyl groups.
The supernatant of the fraction treated with the protein precipi¬ tant is applied to the appropriate chromatographic material and optionally washed. Elution of the factor IX bound to the column and still containing factor X can be performed with a buffer containing the protein precipitant in a lower concentration, the ionic strength of the eluent solution thus being reduced with respect to that of the application solution. The fraction com¬ prising factor IX eluting from the chromatographic column which contains HIC material is collected and subjected to further desalting steps using appropriate means. This can be performed, for instance, by ultrafiltration and/or diafiltration.
Further separation of factor IX, for example, from accompanying factor X, is performed in a preferred embodiment of the present invention by affinity chromatography on a heparin modified substrate. When the ionic strength of the solution containing the factors is relatively low, the latter will bind to the chromato¬ graphic material. Elution of interfering factor X, if any, is achieved by treatment with a solution containing sodium chloride in concentrations of from 150 to 300 mmol/1. Under such condi¬ tions, factor IX will remain bound to the heparin affinity substrate. Upon increasing the ionic strength of the aqueous solution to about twice its value, factor IX starts separating from the surface of the affinity substrate.
Virus inactivation may be performed by chemical and/or physical processes. The physical virus inactivation method essentially consists in heat, treating the respective fraction at 60 to 65°C for 5 to 30 hours. Such heat treatment can be performed, in particular, following the heparin affinity chromatography. The chemical virus inactivation consists, for example, in a treatment of a fraction containing factor IX with non-ionic surfactants and dialkyl or trialkyl phosphates. In particular, combinations of Tween and tri-n-butyl phosphate (TNBP) may be used. Methods of virus inactivation are described in EP 0131740 or in Horowitz et al., Blood, 79 (1992) 826.
Virus inactivation methods may also be combined, such as described in WO 94/17834. Preferably, chemical virus inactivation is performed after the ultrafiltration/diafiltration following the hydrophobic chromatography.
By applying the process according to the invention, the overall yield of high purity factor IX can be increased to 20 to 30%, based on plasma.
The figure shows the process according to the invention with subsequent chromatographic purification steps in the form of a flow chart. The arrows indicate which fractions are separated off and which remain in the corresponding eluates and supernatants.
The following example will illustrate the invention.
Frozen citrate plasma is thawed and agitated at 0 to 3°C. Factor VIII and fibrinogen are separated by centrifugation. The cryopoor plasma fraction obtained contains vitamin K dependent coagulation factors with a specific activity of about 0.01 IU/mg of protein. The subsequent capture step includes solid phase extraction or chromatography on DEAE ion exchangers, separating IgG and albumin. The vitamin K dependent coagulation factors are present in an activity of from 10 to 50 IU/ml, corresponding to an enrichment factor of about 3500, based on factor IX.
The capture step is now followed by the actual purification. To the fraction resulting from the capture step is added an ammonium sulfate solution to give a final concentration of about 1.9 mol/1. C and S proteins are removed by about 50% whereas factor II is removed by 70 to 90% and factor VII almost quantita- tively. The supernatant obtained from the ammonium sulfate precipitation is subjected to hydrophobic interaction chromato¬ graphy on an appropriately modified tentacle gel. The concentra¬ tion of ammonium sulfate in the application solution was about 1.75 mol/1. The application buffer also contains phosphate ions. Hydrophobic interaction chromatography will result in residual factor VII and factor IX being bound. Factor X will bind to the material at 70 to 80%. Elution of the factor IX/factor X mixture is performed with a solution of ammonium sulfate containing from 1.2 to 1.4 mol/1. The eluent is free of factor VII and has essentially no proteolytic activity. The specific activity of factor IX in the factor IX/factor X mixture is from 5 to 15 IU/mg of protein.
The ammonium sulfate present in the eluate is removed by ultra- filtration and diafiltration. Virus inactivation with detergents is performed by treatment with about 1% Tween 80/0.3% TNBP.
Then, after separating the detergent, the fraction obtained is subjected to heparin affinity chromatography. Factors X and IX will bind to the heparin gel at low osmolarities . Factor X is obtained by washing with a buffer containing 0.25 mol/1 of NaCl . Factor IX will elute upon increasing the sodium chloride con¬ centration to 0.45 mol/1. Thereafter, factor IX is present in the eluate at 30 to 50 IU/ml with a specific activity of > 100.
The fraction thus obtained containing factor IX is desalted and lyophilized.

Claims

C L A I M S
1. A process for the preparation of factor IX from biological sources by chromatography, characterized in that prior to any chromatographic separations said source is treated with a protein precipitant.
2. The process according to claim 1, wherein said biological source is blood plasma or plasma depleted of factor VIII and fibrinogen by separation of the cryoprecipitate
(cryopoor plasma) .
3. The process according to claim 1 or 2, wherein said protein precipitant is ammonium sulfate.
4. The process according to at least one of claims 1 to 3 , wherein said protein precipitant is used in a concentration of from 1.5 to 2.3 mol/1 (final concentration) .
5. The process according to at least one of claims 1 to , wherein removal of the protein precipitant and enrichment of factor IX by adsorption of factor IX to a chromato¬ graphic material capable of being employed for hydrophobic interaction chromatography (HIC) are performed following protein precipitation.
6. The process according to claim 5, wherein said chromato¬ graphic material having adsorbed factor IX is treated with an aqueous solution having an ionic strength resulting in separation of factor IX from said HIC material.
7. The process according to claim 5 and/or 6, wherein the fractions obtained after separation of factor IX from said HIC material are subjected to a process step which reduces the salt concentration of the solution containing factor IX, e.g. by ultrafiltration/diafiltration.
8. The process according to claim 7, which is followed by affinity chromatography on a heparin modified substrate material .
9. The process according to any of claims 1 to 8, wherein virus inactivation is performed by chemical and/or physical means .
10. The process according to claim 9, wherein said physical virus inactivation comprises heat treatment at 60 to 65°C for 5 to 30 hours, in particular following said affinity chromatography on heparin according to claim 8.
11. The process according to claim 9, wherein said chemical virus inactivation comprises treatment of the sample containing factor IX with non-ionic detergents/dialkylated or trialkylated phosphates.
12. Factor IX obtained by the process according to at least one of claims 1 to 11.
PCT/EP1996/000636 1995-02-25 1996-02-14 A process for the preparation of factor ix from biological sources Ceased WO1996027003A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
UA97084352A UA46005C2 (en) 1995-02-25 1996-02-14 METHOD OF OBTAINING FACTOR IX FROM BIOLOGICAL SOURCES AND FACTOR OBTAINED BY THE INDICATED METHOD
AT96904778T ATE194167T1 (en) 1995-02-25 1996-02-14 A PROCESS FOR THE PRODUCTION OF FACTOR IX OF BIOLOGICAL ORIGIN
EP96904778A EP0811058B1 (en) 1995-02-25 1996-02-14 A process for the preparation of factor ix from biological sources
AU48761/96A AU697217B2 (en) 1995-02-25 1996-02-14 A process for the preparation of factor IX from biological sources
DE69609054T DE69609054T2 (en) 1995-02-25 1996-02-14 A PROCESS FOR THE PRODUCTION OF FACTOR IX BIOLOGICAL ORIGIN
US08/894,654 US5919909A (en) 1995-02-25 1996-02-14 Process for the preparation of factor IX from biological sources
EA199700196A EA000222B1 (en) 1995-02-25 1996-02-14 A process for preparation of factor ix from biological sources and factor ix, obtained thereafter
CA002213577A CA2213577C (en) 1995-02-25 1996-02-14 A process for the preparation of factor ix from biological sources
JP8525986A JPH11500910A (en) 1995-02-25 1996-02-14 Method for preparing factor IX from a biological source
DK96904778T DK0811058T3 (en) 1995-02-25 1996-02-14 Process for preparing factor IX from biological sources
FI973469A FI119377B (en) 1995-02-25 1997-08-22 Process for preparing Factor IX from biological sources
GR20000401725T GR3034035T3 (en) 1995-02-25 2000-07-27 A process for the preparation of factor ix from biological sources

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19506633.2 1995-02-25
DE19506633A DE19506633A1 (en) 1995-02-25 1995-02-25 Process for the preparation of factor IX from biological sources

Publications (1)

Publication Number Publication Date
WO1996027003A1 true WO1996027003A1 (en) 1996-09-06

Family

ID=7755037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/000636 Ceased WO1996027003A1 (en) 1995-02-25 1996-02-14 A process for the preparation of factor ix from biological sources

Country Status (20)

Country Link
US (1) US5919909A (en)
EP (1) EP0811058B1 (en)
JP (1) JPH11500910A (en)
KR (1) KR100436857B1 (en)
CN (1) CN1105779C (en)
AT (1) ATE194167T1 (en)
AU (1) AU697217B2 (en)
CA (1) CA2213577C (en)
DE (2) DE19506633A1 (en)
DK (1) DK0811058T3 (en)
EA (1) EA000222B1 (en)
ES (1) ES2147365T3 (en)
FI (1) FI119377B (en)
GR (1) GR3034035T3 (en)
IL (1) IL117157A (en)
MY (1) MY119366A (en)
PT (1) PT811058E (en)
UA (1) UA46005C2 (en)
WO (1) WO1996027003A1 (en)
ZA (1) ZA961450B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033140A1 (en) * 2003-09-30 2005-04-14 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Highly pure blood coagulation factor ix preparation and method of purifying the same

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19506633A1 (en) * 1995-02-25 1996-08-29 Octapharma Ag Process for the preparation of factor IX from biological sources
AT405608B (en) * 1997-04-08 1999-10-25 Immuno Ag METHOD FOR INACTIVATING PATHOGENS, ESPECIALLY VIRUSES, IN A BIOLOGICAL MATERIAL
KR100567448B1 (en) * 2003-11-05 2006-04-04 주식회사 인투젠 Milk pretreatment method of transgenic animals and purification method of human protein
US7425539B2 (en) 2004-03-19 2008-09-16 Baxter International Inc. Factor IXa for the treatment of bleeding disorders
US10928366B2 (en) * 2007-01-26 2021-02-23 Sigma-Aldrich Co. Llc Compositions and methods for combining protein precipitation and solid phase extraction
US10434492B2 (en) * 2007-01-26 2019-10-08 Sigma-Aldrich Co. Llc Compositions and methods for solid phase extraction of lipids
AU2011234521B2 (en) * 2010-03-30 2015-04-23 Octapharma Ag A process for purifying Vitamin K dependent proteins such as coagulation factor IX
CN104560925B (en) * 2014-12-30 2017-11-03 山东泰邦生物制品有限公司 A kind of method that activation prepares human thrombin in chromatography waste liquid from humanclottingfactorⅨ
CN107540743A (en) * 2017-10-11 2018-01-05 南岳生物制药有限公司 A kind of method that bilayer chromatography prepares human fibrinogen
CN111378029B (en) * 2018-12-29 2023-05-05 四川远大蜀阳药业有限责任公司 Preparation method of human coagulation factor IX

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0131740A2 (en) 1983-07-14 1985-01-23 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
WO1992015324A1 (en) 1991-03-01 1992-09-17 Rhone-Poulenc Rorer International (Holdings) Inc. Preparation of factor ix
WO1994017834A1 (en) 1993-02-09 1994-08-18 Octapharma Ag Method for inactivating viruses devoid of lipid envelopes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3473407D1 (en) * 1983-05-02 1988-09-22 Immuno Ag Method of inactivating pathogens
EP0317376B2 (en) * 1987-10-23 1996-04-03 Centre Regional De Transfusion Sanguine De Lille Preparation of a concentrate of high-purity human factor IX and of other plasma proteins
AT402261B (en) * 1991-01-25 1997-03-25 Immuno Ag COMPLEX CONTAINING THE coagulation factor IX
DE19506633A1 (en) * 1995-02-25 1996-08-29 Octapharma Ag Process for the preparation of factor IX from biological sources

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0131740A2 (en) 1983-07-14 1985-01-23 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
WO1992015324A1 (en) 1991-03-01 1992-09-17 Rhone-Poulenc Rorer International (Holdings) Inc. Preparation of factor ix
WO1994017834A1 (en) 1993-02-09 1994-08-18 Octapharma Ag Method for inactivating viruses devoid of lipid envelopes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HOROWITZ ET AL., BLOOD, vol. 79, 1992, pages 826
SCOPES, R.K.: "Protein Purification Principles and Practice", 1987, SPRINGER VERLAG, pages: 41 - 55
SCOPES, R.K.: "Protein Purification, Principles and Practice (2nd ed.)", 1987, SPRINGER-VERLAG, NEW YORK, HEIDELBERG, BERLIN, XP002005649 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033140A1 (en) * 2003-09-30 2005-04-14 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Highly pure blood coagulation factor ix preparation and method of purifying the same
JPWO2005033140A1 (en) * 2003-09-30 2008-01-17 財団法人化学及血清療法研究所 High-purity blood coagulation factor IX preparation and purification method thereof
JP4855074B2 (en) * 2003-09-30 2012-01-18 一般財団法人化学及血清療法研究所 High-purity blood coagulation factor IX preparation and purification method thereof

Also Published As

Publication number Publication date
ATE194167T1 (en) 2000-07-15
EA000222B1 (en) 1998-12-24
CA2213577C (en) 2005-01-04
KR100436857B1 (en) 2004-09-21
FI119377B (en) 2008-10-31
JPH11500910A (en) 1999-01-26
EP0811058A1 (en) 1997-12-10
UA46005C2 (en) 2002-05-15
ES2147365T3 (en) 2000-09-01
IL117157A0 (en) 1996-06-18
CA2213577A1 (en) 1996-09-06
AU697217B2 (en) 1998-10-01
GR3034035T3 (en) 2000-11-30
EA199700196A1 (en) 1998-02-26
EP0811058B1 (en) 2000-06-28
FI973469A0 (en) 1997-08-22
AU4876196A (en) 1996-09-18
ZA961450B (en) 1996-08-27
DE69609054D1 (en) 2000-08-03
CN1181782A (en) 1998-05-13
DE19506633A1 (en) 1996-08-29
US5919909A (en) 1999-07-06
FI973469L (en) 1997-08-22
CN1105779C (en) 2003-04-16
PT811058E (en) 2000-10-31
DE69609054T2 (en) 2001-03-08
IL117157A (en) 1999-12-22
MY119366A (en) 2005-05-31
DK0811058T3 (en) 2000-10-16
KR19980702453A (en) 1998-07-15

Similar Documents

Publication Publication Date Title
JP3094167B2 (en) Purification method of immune serum globulin
JP4218980B2 (en) Immunoglobulin G concentrate for treatment and method for producing the concentrate
CA2024667C (en) Process for preparing a concentrate of blood coagulation factor viii-von willebrand factor complex from total plasma
AU697217B2 (en) A process for the preparation of factor IX from biological sources
EP0239565B1 (en) Method of separating proteins
CA2059979C (en) Complex containing coagulation factor ix
EP0391974B1 (en) Process for the purification of vitamin k-dependent blood clotting factors
HU219828B (en) Method for Isolation and Purification of Vitamin K Dependent Proteins
CN1175105C (en) Purification of vitamin K-dependent proteins by means of membrane chromatography
JP2573467B2 (en) Pharmaceutical compositions suitable for therapeutic use containing factor IX protein
WO1995011966A1 (en) Human activated protein c preparation and process for producing the same
US5445958A (en) Process for purifying blood clotting factors
Pierce Purification of mammalian kallikreins, kininogens, and kinins
Miribel et al. The use of dye-ligand affinity chromatography for the purification of non-enzymatic human plasma proteins
KR960705841A (en) PROCESS FOR PRODUCING A VIRUS-INACTIVATED FACTOR VIII-CONTAINING FRACTION BY CHROMATOGRAPHIC METHODS
JPH0739375A (en) Method for purifying plasminogen
Garg et al. Therapeutic Grade Proteins
AU627446C (en) Chemical process
KR960005734B1 (en) Purification method for fibrinogen protease
KR100738022B1 (en) Purification method of human von Willebrand factor protein by milk pretreatment of transgenic pig
Scopes Optimization of procedures; recombinant protein techniques
KR19980075977A (en) Method for Purifying Aminopeptidase M from Porcine Kidney

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96193308.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU BB BG BR CA CN CZ EE FI GE HU IS JP KG KP KR LK LR LT LV MD MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN AZ BY KG KZ RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996904778

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1996 525986

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2213577

Country of ref document: CA

Ref document number: 2213577

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 973469

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 1019970705853

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 199700196

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 08894654

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1996904778

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019970705853

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1996904778

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1019970705853

Country of ref document: KR